| Identification | Back Directory | [Name]
Urea, N'-(4,5,6,11,12,13-hexahydro-2-Methyl-4-oxo-11-propyl-2H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-8-yl)-N-Methyl-N-phenyl- | [CAS]
856692-39-2 | [Synonyms]
CEP-14083
DRYABXKGCXCACQ-UHFFFAOYSA-N
Urea, N'-(4,5,6,11,12,13-hexahydro-2-Methyl-4-oxo-11-propyl-2H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-8-yl)-N-Methyl-N-phenyl- | [Molecular Formula]
C31H30N6O2 | [MDL Number]
MFCD18782698 | [MOL File]
856692-39-2.mol | [Molecular Weight]
518.609 |
| Hazard Information | Back Directory | [Description]
CEP-14083 is a potent ALK inhibitor that has shown activity in an NPM/ALK?–carrying T-cell lymphoma in vitro study. Presumably, this compound binds to the hinge region of the kinase in an ATP-competitive manner. CEP-14083 displays a potent activity against ALK in enzymatic assays (IC50 = 11 nmol/L). Further, CEP-14083 is also able to inhibit the insulin receptor at a concentration within a nanomolar range. In a preclinical assay, CEP-14083 showed that, via NPM/ALK TK inhibition, it could control the expression of molecules that determine T-cell identity and signaling in lymphoma cells. CEP-14083 has shown preclinical activity in both cell lines and animal models harboring ALK alteration. | [Uses]
CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma[1][2]. | [References]
[1] Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2(2):72-86. DOI:10.3978/j.issn.2218-6751.2013.03.1
[2] Marzec M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7. DOI:10.1073/pnas.0810958105 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|